Automated, miniaturized and accelerated drug discovery: AMADEUS

Project Information

AMADEUS

Grant agreement ID: 101098001

DOI

10.3030/101098001

EC signature date 25 May 2023

Start date 1 January 2024

End date 31 December 2028

Funded under

• European Research Council (ERC)

Total cost

€ 3 409 401,00

EU contribution

€ 3 409 401,00

Coordinated by

UNIVERZITA PALACKEHO V OLOMOUCI
Czechia

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (7)

Exploring Aspartate Transcarbamoylase: A Promising Broad‐Spectrum Target for Drug Development

Author(s): Siyao Chen, Queenie Mondile, XiaoChen Du, Chao Wang, Mayur Mukim, Carsten Wrenger, Alexander S. S. Dömling, Özlem Tastan Bishop, Matthew R. Groves
Published in: ChemBioChem, Issue 26, 2025, ISSN 1439-4227
Publisher: Wiley
DOI: 10.1002/CBIC.202401009

Precipitation-first synthesis and deep profiling of a 1200-member acrylamide library for covalent drug discovery

Author(s): Pravin Patil, Emis Ingenito, Riccardo Fusco, Imma Capriello, Zhirui Guan, Anuja Bhalkikar, John Gibbons, Tomas Korba, Stanislav Bashkyrtsev, Oleh Tkachenko, Alexander Dömling
Published in: Green Chemistry, Issue 27, 2025, ISSN 1463-9262
Publisher: Royal Society of Chemistry (RSC)
DOI: 10.5281/ZENODO.15496516

Novel FOXM1 inhibitor STL001 sensitizes human cancers to a broad-spectrum of cancer therapies

Author(s): Sanjeev Raghuwanshi, Xu Zhang, Zarema Arbieva, Irum Khan, Hisham Mohammed, Z. Wang, Alexander Domling, Carlos Jaime Camacho, Andrei L. Gartel
Published in: Cell Death Discovery, Issue 10, 2024, ISSN 2058-7716
Publisher: Springer Science and Business Media LLC
DOI: 10.1038/S41420-024-01929-0

Novel Spirooxindole–Benzofuran Scaffold: Potential Inhibition Against Hepatocellular Carcinoma by Targeting MDM2‐p53 Interaction

Author(s): Muhanna K. Al‐Muhanna, Assem Barakat, Mohammad Shahidul Islam, M. Ali, Abdulmajeed Abdullah Alayyaf, Komal Zia, Zaheer Ul‐Haq, Alexander Dömling, Fardous F. El‐Senduny, Farid A. Badria
Published in: ChemistrySelect, Issue 9, 2025, ISSN 2365-6549
Publisher: Wiley
DOI: 10.1002/SLCT.202403953

Balinatunfib: A Clinical Oral Small Molecule TNFα Inhibitor

Author(s): Alexander Dömling, Tad A. Holak
Published in: ChemMedChem, Issue 20, 2025, ISSN 1860-7179
Publisher: Wiley
DOI: 10.1002/CMDC.202500258

Multicomponent Reactions: A Promising Approach to Isotope Labeling

Author(s): Alexander Domling, Philip H. Elsinga, Siyu Xiao, Antonio Conte, Bart T. Cornelissen
Published in: Synlett, Issue 35, 2024, ISSN 0936-5214
Publisher: Georg Thieme Verlag KG
DOI: 10.1055/A-2331-6399

CBL-B – An upcoming immune-oncology target

Author(s): Riccardo Fusco, Zeinab Saedi, Imma Capriello, Andriy Lubskyy, Alexander Dömling
Published in: Expert Opinion on Therapeutic Patents, Issue 35, 2025, ISSN 1354-3776
Publisher: Informa UK Limited
DOI: 10.1080/13543776.2024.2412567